MedTrace Logo

Preliminary Safety and Efficacy of XT-150 in Facet Joint Osteoarthritis

NCT04841512 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2022-03-17

No results posted yet for this study

Summary

Preliminary safety and efficacy of XT-150 in the synovial capsule of osteoarthritic facet joints in the vertebra of the spine.

Conditions

  • Osteoarthritis, Spine

Interventions

BIOLOGICAL

XT-150

non-viral Plasmid DNA encoding an IL-10 variant transgene

Sponsors & Collaborators

  • Xalud Therapeutics, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-31
Primary Completion
2022-03-01
Completion
2022-03-01
FDA Drug
Yes

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04841512 on ClinicalTrials.gov